Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | CPRX | Options to purchase common stock | Options Exercise | $0 | -25K | -0.68% | $0.00 | 3.64M | Aug 18, 2022 | Common Stock | 25K | $2.53 | Direct | F7 |
transaction | CPRX | Options to purchase common stock | Options Exercise | $0 | -50K | -1.37% | $0.00 | 3.59M | Aug 18, 2022 | Common Stock | 50K | $2.53 | Direct | F7 |
transaction | CPRX | Options to purchase common stock | Options Exercise | $0 | -50K | -1.39% | $0.00 | 3.54M | Aug 18, 2022 | Common Stock | 50K | $2.53 | Direct | F7 |
transaction | CPRX | Options to purchase common stock | Options Exercise | $0 | -50K | -1.41% | $0.00 | 3.49M | Aug 18, 2022 | Common Stock | 50K | $2.53 | Direct | F7 |
transaction | CPRX | Options to purchase common stock | Options Exercise | $0 | -125K | -3.58% | $0.00 | 3.37M | Aug 19, 2022 | Common Stock | 125K | $2.53 | Direct | F7 |
Id | Content |
---|---|
F1 | Shares were sold in various lots from $13.93 to $13.97 per share. The listed sales price represents a weighted average price for the shares sold. |
F2 | Shares were sold in various lots from $13.93 to $13.94 per share. The listed sales price represents a weighted average price for the shares sold. |
F3 | Shares were sold in various lots from $13.95 to $14.00 per share. The listed sales price represents a weighted average price for the shares sold. |
F4 | Shares were sold in various lots from $13.95 to $13.98 per share. The listed sales price represents a weighted average price for the shares sold. |
F5 | Shares were sold in various lots from $14.05 to $14.14 per share. The listed sales price represents a weighted average price for the shares sold. |
F6 | Shares were sold to cover the exercise price of options, tax withholding requirements (if applicable) and for personal reasons. The shares were not sold as a result of any agreement with the Company and Mr. McEnany remains an officer of the company. |
F7 | Options vested in three separate tranches beginning on December 30, 2016. |